-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on December 6, Xinhua Pharmaceutical hit the daily limit at the opening.
As of 9:42, the stock rose 7.
35%, with a quotation of 10.
52 yuan, a turnover of 353 million, and a turnover rate of 7.
70%.
The current total market value is 6.
600 billion.
.
It is worth mentioning that the stock has risen by the limit 4 times during the year
.
For this daily limit, the analysis believes that there are two main reasons.
First, the company is mainly engaged in the development, manufacture and sales of chemical raw materials, preparations, chemicals and other products; the company's main products are antipyretic and analgesic raw materials, tablets.
, injections, capsules, pharmaceutical intermediates
.
Second, 17α-hydroxyprogesterone is an important pharmaceutical intermediate for the production of medroxyprogesterone, megestrol and hydrocortisone acetate
.
The above project is a joint venture with Common Pharma.
Construction has started in Shouguang, Shandong.
The joint venture company, Xinhua Pharma, holds 60% of the shares
.
In terms of news, Xinhua Pharma's entry into the medical and aesthetic field has attracted much attention from investors.
The company recently replied on the interactive platform that it is expected to launch the Phoenix needle by the end of this year
.
According to reports, the upcoming "Phoenix Needle" belongs to the second category of mechanical products, mainly through micro-needle operation or photoelectric postoperative application, etc.
, and has a good repair effect on damaged skin and aging skin
.
Previously, Xinhua Pharma once stated that "Phoenix Needle" is the first product of Xinhua Health to enter the medical beauty market.
It is mainly suitable for dermatology in the medical beauty track, and the main ingredient is exosomes
.
"In the future in the medical beauty track, Xinhua Health will successively launch a variety of skin, hair and other products
.
" According to the data, Xinhua Health is jointly funded by Xinhua Pharma and Hualu Investment and other companies, and was established on December 12, 2020.
, Among them, Xinhua Pharmaceuticals owns 49% of the shares and is the actual controller of the company
.
According to Tianyancha, Xinhua Health's business scope includes remote health management services; health consulting services (excluding diagnosis and treatment services); health care services (non-medical); Internet data services
;
In addition, Xinhua Pharma recently issued an announcement stating that the company received the "Approval Notice for Supplementary Drug Application" for Compound Sulfamethoxazole Tablets approved and issued by the State Food and Drug Administration, and the product passed the consistency evaluation of the quality and efficacy of generic drugs
.
It is reported that compound sulfamethoxazole tablets is a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP), which was developed by Sun Pharm INDs and was approved by the FDA in 1973 to be marketed in the United States
.
The drug is a sulfonamide antibacterial drug, which is mainly used to prevent or treat infections caused by sensitive strains
.
As of the date of this announcement, the company has invested approximately RMB 10.
02 million in research and development expenses for the consistency evaluation of compound sulfamethoxazole tablets
.
In response to the abnormal fluctuations in the company's stock, the company issued an announcement on December 6 that it had checked the relevant matters.
After checking, there was no information that the company disclosed in the previous period that needs to be corrected or supplemented; the recent public media has not reported that there may be or has been Unpublished material information that has a great impact on the company's stock trading price; there has been no major change in the company's recent operating conditions and internal and external operating environment
.
In addition, upon inquiries, the controlling shareholder and actual controller did not buy or sell the company's stock during the period of abnormal fluctuations in the company's stock trading
.
According to the third quarterly report of 2021 disclosed by Xinhua Pharmaceuticals, in the first three quarters of 2021, the company achieved operating income of 4.
940 billion yuan, net profit of 285 million yuan, earnings per share of 0.
46 yuan, and a price-earnings ratio of 13.
73
.
As of 9:42, the stock rose 7.
35%, with a quotation of 10.
52 yuan, a turnover of 353 million, and a turnover rate of 7.
70%.
The current total market value is 6.
600 billion.
.
It is worth mentioning that the stock has risen by the limit 4 times during the year
.
For this daily limit, the analysis believes that there are two main reasons.
First, the company is mainly engaged in the development, manufacture and sales of chemical raw materials, preparations, chemicals and other products; the company's main products are antipyretic and analgesic raw materials, tablets.
, injections, capsules, pharmaceutical intermediates
.
Second, 17α-hydroxyprogesterone is an important pharmaceutical intermediate for the production of medroxyprogesterone, megestrol and hydrocortisone acetate
.
The above project is a joint venture with Common Pharma.
Construction has started in Shouguang, Shandong.
The joint venture company, Xinhua Pharma, holds 60% of the shares
.
In terms of news, Xinhua Pharma's entry into the medical and aesthetic field has attracted much attention from investors.
The company recently replied on the interactive platform that it is expected to launch the Phoenix needle by the end of this year
.
According to reports, the upcoming "Phoenix Needle" belongs to the second category of mechanical products, mainly through micro-needle operation or photoelectric postoperative application, etc.
, and has a good repair effect on damaged skin and aging skin
.
Previously, Xinhua Pharma once stated that "Phoenix Needle" is the first product of Xinhua Health to enter the medical beauty market.
It is mainly suitable for dermatology in the medical beauty track, and the main ingredient is exosomes
.
"In the future in the medical beauty track, Xinhua Health will successively launch a variety of skin, hair and other products
.
" According to the data, Xinhua Health is jointly funded by Xinhua Pharma and Hualu Investment and other companies, and was established on December 12, 2020.
, Among them, Xinhua Pharmaceuticals owns 49% of the shares and is the actual controller of the company
.
According to Tianyancha, Xinhua Health's business scope includes remote health management services; health consulting services (excluding diagnosis and treatment services); health care services (non-medical); Internet data services
;
In addition, Xinhua Pharma recently issued an announcement stating that the company received the "Approval Notice for Supplementary Drug Application" for Compound Sulfamethoxazole Tablets approved and issued by the State Food and Drug Administration, and the product passed the consistency evaluation of the quality and efficacy of generic drugs
.
It is reported that compound sulfamethoxazole tablets is a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP), which was developed by Sun Pharm INDs and was approved by the FDA in 1973 to be marketed in the United States
.
The drug is a sulfonamide antibacterial drug, which is mainly used to prevent or treat infections caused by sensitive strains
.
As of the date of this announcement, the company has invested approximately RMB 10.
02 million in research and development expenses for the consistency evaluation of compound sulfamethoxazole tablets
.
In response to the abnormal fluctuations in the company's stock, the company issued an announcement on December 6 that it had checked the relevant matters.
After checking, there was no information that the company disclosed in the previous period that needs to be corrected or supplemented; the recent public media has not reported that there may be or has been Unpublished material information that has a great impact on the company's stock trading price; there has been no major change in the company's recent operating conditions and internal and external operating environment
.
In addition, upon inquiries, the controlling shareholder and actual controller did not buy or sell the company's stock during the period of abnormal fluctuations in the company's stock trading
.
According to the third quarterly report of 2021 disclosed by Xinhua Pharmaceuticals, in the first three quarters of 2021, the company achieved operating income of 4.
940 billion yuan, net profit of 285 million yuan, earnings per share of 0.
46 yuan, and a price-earnings ratio of 13.
73
.
